Turalio (Pexidartinib Hydrochloride) Patent Expiration, LOE Window & CMS Spending

Turalio (Pexidartinib Hydrochloride) by Daiichi Sankyo: FDA Orange Book core substance LOE 2036-05-05 (last listed 2038-07-24), 0 AB generics, $9.5M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDaiichi Sankyo
FDA Application & PathwayN211810 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-05-05
Last Listed Patent or Exclusivity Date2038-07-24
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$9.5M
2024 Medicare Part D Spend$2.4M
2024 Medicaid Spend$7.1M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 18.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.